Investors including Nan Fung and Tekla Capital have increased the ophthalmic treatment developer's series B round to $35.9m, following a Novartis-led tranche a year ago.
Switzerland-based ophthalmic therapy developer Oculis increased a series B round featuring Nan Fung Life Sciences, a subsidiary of property developer Nan Fung, to CHF35.5m ($35.9m) on Friday.
The company added CHF15.5m from investors including Nan Fung Life Sciences, investment adviser Tekla Capital Management and undisclosed existing investors to a CHF20m first tranche that closed in January 2018.
The first tranche was co-led by Novartis Venture Fund, a corporate venturing vehicle for drug producer Novartis, along with the Nan Fung-backed…
